Company Overview and News

0
Minda Industries Limited - Disclosure under SEBI Takeover Regulations

5h nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
MINDAIND 532539

0
Minda Industries Limited - Record Date

2018-06-11 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
MINDAIND 532539

0
Minda Industries Limited - Disclosure under SEBI Takeover Regulations

2018-06-05 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
MINDAIND 532539

0
Minda Industries Limited - Disclosure under SEBI Takeover Regulations

2018-06-05 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
MINDAIND 532539

0
Minda Industries Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-06-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
MINDAIND 532539

0
Minda Industries Limited - Shareholders meeting

2018-06-02 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
MINDAIND 532539

0
10th Edition of MANUFACTURING IT SUMMIT to be Held on June 14th

2018-05-25 freepressjournal.in
The Indian manufacturing sector is sprinting at a never before pace fueled by the dynamic technological innovations and a growing number of organizations are proactively adapting these emerging advancements. The manufacturing companies are moving swiftly from mass production to customized production using technology and digital platforms. What’s important to note is that, this is just one among many transformations the industry is concurring due to adaptive advancements in IT, for manufacturing.
GABRIEL INDIAGLYCO AUROPHARMA 524804 ARBQY MINDAIND 505714 500201 532539

0
10th Edition of manufacturing IT summit to be held on June 14

2018-05-25 freepressjournal.in
The 10th edition manufacturing IT summit will be held on June 14 in Mumbai. The summit is the perfect platform for C-suite executives of manufacturing companies across industries, to come together and discuss the IT trends in Indian manufacturing industry, network with peers, and build ROI-backed business relations. This summit also facilitates a marketplace for the buyers to meet with the sellers offering disruptive solutions on the emerging trends in manufacturing’s IT.
GABRIEL INDIAGLYCO AUROPHARMA 524804 ARBQY MINDAIND 505714 500201 532539

1
Volumes of these 5 stocks rose by up to 7,000% today

2018-05-23 moneycontrol
Benchmark indices continued to trade weak, with the Nifty down 53 points at 10,483 and the Sensex down 129 points at 34,521.
AMKD BHUSANSTL MINDAIND 532539 AMTEKAUTO 534809 PCJEWELLER 520077 500055

0
Minda Industries Limited - Investor Presentation

2018-05-23 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
MINDAIND 532539

0
Manufacturing IT summit: A call for manufacturers

2018-05-23 freepressjournal.in
The Indian manufacturing sector is sprinting at a never before pace. It is fuelled by the dynamic technological innovations and a growing number of organisations that are proactively adapting these emerging advancements. The 10th edition of manufacturing IT summit which is the perfect platform for C-suite executives of manufacturing companies across industries, will take place in June 14, 2018. The executives will come together and discuss the IT trends in Indian manufacturing industry, network with peers, and build ROI-backed business relations.
GABRIEL INDIAGLYCO AUROPHARMA 524804 ARBQY MINDAIND 505714 500201 532539

0
2:1 bonus from Minda Ind

2018-05-22 thehindubusinessline
Our Bureau The board of directors of Minda Industries on Tuesday recommended issue of bonus shares to the shareholders of the company in the ratio of two shares of ₹2 each fully paid-up for every one share held.
MINDAIND 532539

0
Minda Industries Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-05-22 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
MINDAIND 532539

0
Minda Industries Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-05-22 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
MINDAIND 532539

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

3h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...